16 results about "Trigeminal neuralgia" patented technology

The application discloses a device for judging the decompression effect of intraoperative trigeminal neuralgia, and relates to the technical field of medical monitoring devices, comprising a forceps body, a collection probe is arranged at the tip of the forceps body, a wiring box is arranged on the side of the forceps body away from the collection probe, a distance adjusting mechanism and an auxiliary center positioning mechanism are arranged between the wiring box and the forceps body, the forceps body with adjustable spacing and the distance adjusting mechanism are arranged, the flexible adjustment of the spacing of the collection probe is achieved, the overall signal of the ganglion segment can be detected by increasing the spacing, the smaller nerve area can be focused by reducing the spacing, the signal difference under different spacings is compared, the compression point is accurately positioned, blind decompression is avoided, the auxiliary center positioning mechanism is arranged, the center point of the forceps body and the corresponding position of the collection probe are quickly positioned, the medical staff accurately aims at the trigeminal nerve to be detected, the positioning deviation is avoided, the collection signal is not inaccurate, the trigeminal neuralgia clustering neural network algorithm is combined, a visual distribution view is generated, and the accuracy of decompression effect judgment and the operation efficiency are improved.

The present invention relates to compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4- (trifluoromethoxy)benzyl] amino }sulfonyl)benzoic acid (elismetrep; MT-8554), or a pharmaceutically acceptable salt thereof, for treating or preventing pain, particularly migraine or a trigeminal pain disease or condition such as medication overuse headache, cluster headache, general headache, trigeminal neuralgia, trigeminal neuropathy, trigeminal autonomic cephalalgia, orofacial pain, and dental pain.

The application discloses an oval foramen automatic detection and fine segmentation method based on an anatomic landmark gravity field and a tubular topology enhancement, and specifically relates to the technical field of medical image processing. Firstly, the head CT or MRI image to be processed is subjected to multi-modal space alignment and adaptive contrast enhancement; subsequently, the image is input into an anatomic landmark gravity field network, macroscopic landmarks of a skull base are extracted, a spatial gravity field matrix is constructed, and the model attention is adaptively focused on a small oval foramen high probability area; then, a multi-view tubular structure enhancement encoder is used to extract features of a three-dimensional hole track of the oval foramen, and the interference of non-penetrating bone depressions is inhibited; finally, a three-dimensional penetrating topology constraint mechanism is introduced in the decoding stage, so that the generated three-dimensional model of the oval foramen has correct anatomic connectivity. The application can effectively solve the detection problem of the oval foramen caused by the large individual variation, the small volume and the easy confusion with surrounding holes and fissures, and significantly improves the preoperative planning accuracy of trigeminal neuralgia puncture and other surgeries.

The invention discloses a trigeminal neuralgia percutaneous puncture path planning method and system. The method comprises the following steps: acquiring skull CT (Computed Tomography) image data and MRI (Magnetic Resonance Imaging) image data of a target, and performing three-dimensional reconstruction to obtain an oval foramen bony model and a McLeod cavity three-dimensional model; determining an anatomical entry point, determining a bony channel constraint point based on an oval foramen bony model, and determining an ideal end point of a puncture path based on a McLeod cavity three-dimensional model; taking the anatomical entry point as a path starting point, taking the ideal end point as a path end point target, taking the bony channel constraint point as a path space constraint condition for path passing, and optimizing a target function to obtain an optimal puncture path; based on the McLeod cavity three-dimensional model space volume, determining an individualized balloon injection amount estimation range of a target; and storing the space coordinate and the direction vector of the optimal puncture path and the individualized balloon injection amount estimation range as a standardized digital file. According to the invention, the certainty and safety of the puncture path can be improved.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

A balloon catheter with positioning and protection functions is used for percutaneous microballoon compression surgery to treat trigeminal neuralgia. It includes a balloon assembly (1) and a catheter assembly (2). The balloon assembly (1) includes a first marker point (11), a second marker point (12), a latex balloon (13), and a third marker point (14). The latex balloon (13) consists of two parts. Its distal part has a smaller outer diameter after inflation and serves as the positioning part (131). Its proximal part has a larger outer diameter after inflation and serves as the compression part (132). The second marker point (12) is located at the junction of the positioning part (131) and the compression part (132) of the latex balloon (13) when it is inflated to the normal size. The positioning step on the latex balloon avoids excessive compression of the posterior fossa during the operation. The location of the balloon step is marked by the second marker point. With the help of preoperative 3D modeling, the balloon position is accurately determined, which reduces the difficulty of the operation.

This invention discloses an animal model of trigeminal neuralgia, its construction method, and its applications. This invention successfully constructed an animal model of trigeminal neuralgia and, through behavioral, cellular, and molecular biological experiments, conducted multi-dimensional research to systematically elucidate the association between changes in macrophages and neurons mediated by the NPY-Y2R signaling pathway and trigeminal neuralgia in the animal model. This model can be used for neuroimmunotherapy of trigeminal neuralgia and enables more effective and precise personalized clinical targeted therapy for patients with trigeminal neuralgia.

The present application belongs to the technical field of biological medicine, and particularly relates to a new use of a 5-HT6 receptor agonist in the preparation of a medicine for treating chronic pain complicated with anxiety and depression, and especially an application of the 5-HT6 receptor agonist in the preparation of a medicine for simultaneously treating chronic neuropathic pain and relieving anxiety and / or depression caused by the chronic pain. The present application discloses for the first time that in a pathological state of chronic pain (such as trigeminal neuralgia) secondary anxiety / depression, the expression of 5-HT6R in the mPFC brain region is significantly down-regulated, and a 5-HT6R agonist can dose-dependently specifically relieve anxiety / depression-like behaviors induced by chronic pain, and has no obvious effect on the behavior of normal animals, which indicates that the 5-HT6R agonist has good safety and targeting, and provides a theoretical basis for developing more effective medicines in the clinic.

This utility model provides a head fixation device for interventional surgery, relating to the field of medical device technology. It includes a head support base, a head support body, a head support fixation component, and a back pad. Both the head support fixation component and the head support body are mounted on the head support base. The head support fixation component is used to mount the head support base onto the operating table. The head support body has at least three sets of protrusions, which together form a head fixation area. This design effectively solves the problem of fixing and maintaining the patient's position during interventional radiofrequency ablation surgery for trigeminal neuralgia. The patient lies comfortably, maintaining a tilted-back posture during the procedure, ensuring the puncture angle remains unchanged, reducing the difficulty of the puncture surgery, shortening the operation time, significantly improving the success rate, significantly reducing surgical complications, and significantly improving the surgical outcome.

The present disclosure describes methods of using an alimemazine or a pharmaceutically acceptable salt thereof for treating pain associated with trigeminal neuralgia. The methods of the present disclosure can include administering to a patient in need thereof a therapeutically effective amount of an alimemazine or a pharmaceutically acceptable salt thereof, thereby treating the patient. The methods can include reducing pain in the patient, as determined by patient report or clinician-administered outcome assessments.

The application discloses a traditional Chinese medicine compound preparation for external use for relieving post-herpetic neuralgia and trigeminal neuralgia, which comprises effective components and auxiliary materials; the effective components specifically comprise rhizoma corydalis, rhabdophis nigrscens, chuanxiong rhizome, radix paeoniae alba, radix stellae, zanthoxylum bungeanum, menthol, and borneol; and the auxiliary materials comprise carbomer 940, glycerol, choline chloride, triethanolamine, and disodium edetate. The traditional Chinese medicine preparation can effectively relieve post-herpetic neuralgia and trigeminal neuralgia and has an antipruritic effect.

The present invention relates to a pharmaceutical composition for preventing or treating trigeminal neuralgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient prevention or treatment of trigeminal neuralgia.

The invention relates to the technical field of biological medicines, in particular to application of a CCR1 / 5 inhibitor Met-RANTES in inhibition of pathological pain of trigeminal nerves. According to the invention, CCR1 / 5 is taken as a therapeutic target of chronic pain, and a medicine which is remarkable in analgesic effect, small in side effect and capable of relieving chronic pain and improving pain mood is developed by combining the pharmacological function of an inhibitor Met-RANTES of CCR1 / 5. The Met-RANTES inhibits a central nervous system chemokine receptor CCRR1 / 5 in a targeted manner in a regular nasal administration manner, so that pathological mechanical pain-sensitive response and accompanying negative emotion caused by chronic compression of trigeminal nerves can be remarkably relieved, and pain feeling is relieved. In addition, the analgesic effect of the drug combination of the Met-RANTES and the carbamazepine is more obvious than that of the drug combination of the Met-RANTES and the carbamazepine which are independently used. The nasal delivery mode enables the medicine to directly reach the central nervous system, and reduces side effects of the whole body.

This invention discloses the application of substances that regulate the pain microenvironment and reshape the balance of the ascending pain perception-descending inhibition pathway in the preparation of drugs for the prevention and treatment of trigeminal neuralgia. It also verifies that after trigeminal nerve injury, the levels of reactive oxygen species (ROS) and TRPA1 channel protein expression increase in trigeminal neuralgia (TG). Improving the oxidative stress environment and silencing the NRF2 gene to assist in the regulation of TRPA1 channel protein can effectively downregulate the expression of pro-analgesic and inflammatory factors, significantly reducing orofacial pain sensitivity. This invention uses the pain microenvironment and the ascending pain perception-descending inhibition pathway as novel targets, providing specific drugs and diagnostic tools for the treatment of trigeminal neuralgia, and has significant clinical value.

The application provides a zhisin blood stasis treating composition for treating trigeminal neuralgia, which is formed by scientifically matching six traditional Chinese medicines, such as chuanqiong, jiangcan and shichangpu. Through optimizing the extraction process and the preparation method, the stability and the bioavailability of the medicine are significantly improved. The clinical research shows that the total effective rate of the composition reaches 92.5%, the recurrence rate is as low as 6.5%, and the safety is good, so that a new solution is provided for the treatment of trigeminal neuralgia.